Medtronic launches post-market SCS programming study

Medtronic (NYSE:MDT) said today it launched a post-market clinical study of its Evolve SM workflow spinal cord stimulation optimization program, having enrolled the first patient in the study. The first patient in the trial was enrolled at Wilmington, Del.’s Center for Interventional Pain & Spine, the company said. “Our goal is to improve or restore function. Even with all of today’s technological advances, chronic pain can be challenging to manage; this is further complicated by the opioid crisis. Standard treatment guidance has the potential to help optimize pain relief, and the Vectors Post Market study will provide valuable data about the efficacy of high dose stimulation using standardized programming through the Evolve workflow,” Dr. Michael Fishman of the Center for Interventional Pain & Spine said in a prepared statement. The Vectors post market clinical study will explore the use of Evolve workflow optimization programming for Fridley, Minn.-based SCS units, including Medtronic’s Intellis SCS platform. The program is designed to standardize guidance to balance low-dose and high-dose therapy settings. “The Vectors study will generate meaningful data about the use of the Evolve workflow and will help further physicians’ understanding of how to use this simple, versatile approach to enable effective, long-term pain relief with SCS. Knowing how to best use non-opioid treatment options – like the Intellis SCS platfo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neuromodulation/Neurostimulation Pain Management Medtronic Source Type: news